Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma. Issue 7 (7th June 2022)

• Record Type: Journal Article
• Authors: Muramatsu, Ayako; Kobayashi, Tsutomu; Kawaji-Kanayama, Yuka; Uchiyama, Hitoji; Sasaki, Nana; Uoshima, Nobuhiko; Nakao, Mitsushige; Takahashi, Ryoichi; Shimura, Kazuho; Kaneko, Hiroto; Kiyota, Miki; Wada, Katsuya; Chinen, Yoshiaki; Hirakawa, Koichi; Fuchida, Shin-ichi; Shimazaki, Chihiro; Mizutani, Shinsuke; Tsukamoto, Taku; Shimura, Yuji; Taniwaki, Masafumi; Teramukai, Satoshi; Kuroda, Junya
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 7(2022)
• Page Start: 1678
• Page End: 1685
• Publication Date: 2022-06-07
• Subjects: Cardiovascular adverse events -- carfilzomib -- hypertension -- interleukin-6 -- multiple myeloma; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2038373
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Carfilzomib (CFZ) constitutes powerful combinatory therapy for relapsed/refractory multiple myeloma (RRMM); however, cardiovascular adverse events (CVAEs) have been shown as major treatment obstacles with the use of CFZ. Along with our multi-institutional prospective observational study by the Kyoto Clinical Hematology Study Group on the efficacy and safety of CFZ-based treatments (UMIN000025108), we here performed an ad hoc analysis of CFZ-related CVAEs in 50 patients with RRMM. We analyzed the association between CFZ-related CVAEs and pre-planned examinations, including patients' background, electrocardiographic findings, echocardiographic findings, and serum/plasma levels of 18 potential candidate biomarkers. The common CVAEs were hypertension (42%), arrhythmia (14%), and prolongation of QT corrected interval (10%), whereas no serious CVAEs occurred. The pretreatment serum level of interleukin-6 was identified as a significant risk factor for CFZ-related hypertension. This study revealed hypertension as the most frequent CFZ-related CVAE and suggested that baseline serum interleukin-6 is a useful predictor for CFZ-induced hypertension.